{
  "pmcid": "4039034",
  "sha256": "a1023aa64b3b2fbf28feec1bf82dcbe06e6a3ced7756bd603532fa14641ecede",
  "timestamp_utc": "2025-11-09T15:57:02.885943+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.539100478468903,
    "reading_ease": 30.94275598086125,
    "word_count": 275
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Objective": {
        "score": 1,
        "evidence": "Purpose: To evaluate the changes in functional status and quality of life after TAVR."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Two reviewers independently extracted the mean change (follow-up – baseline) in primary outcomes."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Most studies showed a clinically important decrease in NYHA class at 6–11 months (range: −0.8, −2.1), 12–23 months (−0.8, −2.1), 24–35 months (−1.2, −2.6), and ≥36 months (−1.2, −1.6)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 4,
    "max_score": 25
  }
}